The FDA will evaluate Teva Pharmaceutical Industries' biologics-license application for XM02, a booster of white blood cells and a biosimilar of Amgen's Neupogen. In its filing, Teva stated that it plans to market the drug as Neutroval. The generic-drug maker already markets the treatment in Europe, where a regulatory pathway for biosimilars already exists.

Full Story:

Related Summaries